Dipal Doshi - 01 Mar 2022 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role: President and CEO, Director
Signature: /s/ Jared Cohen, as Attorney-in-Fact
Issuer symbol: TRDA
Transactions as of: 01 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 03 Mar 2022, 15:08:54 UTC
Previous filing: 18 Jan 2022
Next filing: 29 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRDA	Common Stock	Award	$0	+30,250	+16%	$0.000000	214,710	01 Mar 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRDA	Stock Option (Right to Buy)	Award	$0	+181,500		$0.000000	181,500	01 Mar 2022	Common stock	181,500	$11.57	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
F2	Consists of (i) 172,467 shares of common stock (ii) 11,993 shares of restricted common stock issued upon early exercise of stock options, and (iii) 30,250 RSUs reported in this transaction.
F3	25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026.